Evidence map›Paper›PMID 34115964›Full record

ArticleImmunity2021

Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation.

Hongxu Xian, Yuan Liu, Alexandra Rundberg Nilsson, Raphaella Gatchalian, Timothy R Crother, Warren G Tourtellotte, Yi Zhang, German R Aleman-Muench, Gavin Lewis, Weixuan Chen and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 259 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 2 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

259 citing papers in PubMed, 2 syntheses or guidelines pooled it, 381 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Endothelial cell-specific knockout of ATG5 ameliorates inflammation and renal fibrosis by regulating pyroptosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

199 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Hongxu XianLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
Yuan LiuLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
Alexandra Rundberg NilssonLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
Raphaella GatchalianLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
Timothy R CrotherDepartments of Biomedical Sciences and Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Warren G TourtellotteDepartments of Pathology, Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center. Los Angeles, CA 90048, USA; Samuel Oschin Cancer Center, Cedars-Sinai Medical Center. Los Angeles, CA 90048, USA.
Yi ZhangDepartments of Pathology, Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center. Los Angeles, CA 90048, USA.
German R Aleman-MuenchCVM discovery, Immunometabolism, Janssen Research & Development, San Diego CA 92121, USA.
Gavin LewisCVM discovery, Immunometabolism, Janssen Research & Development, San Diego CA 92121, USA.
Weixuan ChenJanssen Research & Development, LLC, San Diego, CA, USA.
Sarah KangLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
Melissa LuevanosNeurodegeneration New Medicines Center and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
Dorit TrudlerNeurodegeneration New Medicines Center and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
Stuart A LiptonNeurodegeneration New Medicines Center and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA.
Pejman SorooshCVM discovery, Immunometabolism, Janssen Research & Development, San Diego CA 92121, USA.
John TeijaroDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Juan Carlos de la TorreDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Moshe ArditiDepartments of Biomedical Sciences and Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA. Electronic address: karinoffice@ucsd.edu.
Elsa Sanchez-LopezLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, UCSD, La Jolla, CA 92093, USA.
University of California San Diego · USScripps Research Institute · USCedars-Sinai Medical Center · USJanssen (United States) · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Yeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8M
Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
REGULATION OF NFKB AND IKK BY PROINFLAMMATORY STIMULIR01AI043477 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 1998 to 2017
$7.4M
Role of IL-1 in Bacterial ligand-induced vasculitis and myocarditisR01AI072726 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI ARDITI, MOSHE · 2008 to 2020
$4.5M
Dynamic Interactions of the S-Nitrosoproteome in Type 2 Diabetes/Metabolic Syndrome and Alzheimer’s DiseaseRF1AG057409 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2020
$4.1M
Resource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2018 to 2022
$3.9M
Elp1 function in Familial DysautonomiaR01NS095894 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2016 to 2019
$1.6M
Role of choline metabolism in activated macrophage phenotypesK01AR077111 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANCHEZ-LOPEZ, ELSA · 2020 to 2024
$580k
Mentoring and Research in Mouse PathobiologyK26OD010945 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2012 to 2014
$471k
Mentoring and Research in Mouse PathobiologyK26RR026099 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2010 to 2011
$317k
NCI NIH HHS P30 CA023100NCI NIH HHS U54 CA260591NCRR NIH HHS K26 RR026099NIAID NIH HHS R01 AI043477NIAID NIH HHS R01 AI072726NIAMS NIH HHS K01 AR077111NIAMS NIH HHS P30 AR073761NIA NIH HHS RF1 AG057409NIEHS NIH HHS P42 ES010337NIH HHS K26 OD010945NINDS NIH HHS R01 NS095894
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS), an inflammatory condition with high mortality rates, is common in severe COVID-19, whose risk is reduced by metformin rather than other anti-diabetic medications. Detecting of inflammasome assembly in post-mortem COVID-19 lungs, we asked whether and how metformin inhibits inflammasome activation while exerting its anti-inflammatory effect. We show that metformin inhibited NLRP3 inflammasome activation and interleukin (IL)-1β production in cultured and alveolar macrophages along with inflammasome-independent IL-6 secretion, thus attenuating lipopolysaccharide (LPS)- and SARS-CoV-2-induced ARDS. By targeting electron transport chain complex 1 and independently of AMP-activated protein kinase (AMPK) or NF-κB, metformin blocked LPS-induced and ATP-dependent mitochondrial (mt) DNA synthesis and generation of oxidized mtDNA, an NLRP3 ligand. Myeloid-specific ablation of LPS-induced cytidine monophosphate kinase 2 (CMPK2), which is rate limiting for mtDNA synthesis, reduced ARDS severity without a direct effect on IL-6. Thus, inhibition of ATP and mtDNA synthesis is sufficient for ARDS amelioration.

Indexed as

Adenosine TriphosphateAnimalsCOVID-19CytokinesDNA, MitochondrialHumansInflammasomesInterleukin-1betaLipopolysaccharidesMetforminMiceNLR Family, Pyrin Domain-Containing 3 ProteinNucleoside-Phosphate KinasePneumoniaRespiratory Distress SyndromeSARS-CoV-2Adenosine TriphosphateCytokinesDNA, MitochondrialInflammasomesInterleukin-1betaLipopolysaccharidesMetforminNLR Family, Pyrin Domain-Containing 3 ProteinNucleoside-Phosphate KinaseARDSCMPK2COVID-19IL-1βIL-6inflammationmetforminmitochondrial DNANLRP3 inflammasomeSARS-CoV-2

Identifiers

PMID34115964
PMCPMC8189765
OpenAlexW3171139414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.